Medical devices, healthcare technology and the business of care
PMA approval · P010015

MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM

Medtronic, Inc. · Decision date Aug 28, 2001

MEDTECHLEDGER EXPLANATIONP010015

What did the FDA approve?

FDA approved the Medtronic InSync biventricular pacing system on August 28, 2001. The approval covers the Model 8040 InSync pulse generator, Model 9980 programmer software, and the Attain LV Model 2187 and Attain CS Model 2188 leads.

The Model 8040 pulse generator is indicated for reducing symptoms of moderate to severe heart failure (NYHA Class III or IV) in patients who remain symptomatic despite stable, optimal medical therapy and have a left ventricular ejection fraction of 35% or less and a QRS duration of 130 ms or more. The Attain LV Model 2187 lead is for use as part of a Medtronic biventricular pacing system, while the Attain CS Model 2188 lead is for permanent atrial or dual-chamber pacing systems or as part of a Medtronic biventricular pacing system.

FDA approval order statement

APPROVAL FOR THE MEDTRONIC INSYNC BIVENTRICULAR PACING SYSTEM INCLUDING THE MODEL 8040 INSYNC PULSE GENERATOR, THE MODEL 9980 PROGRAMMER SOFTWARE, AND THE ATTAIN LV MODEL 2187 AND ATTAIN CS MODEL 2188 LEADS. THE PULSE GENERATOR AND LEADS ARE INDICATED AS FOLLOWS: 1) THE INSYNC MODEL 8040 PULSE GENERATOR IS INDICATED FOR THE REDUCTION OF THE SYMPTOMS OF MODERATE TO SECERE HEART FAILURE (NYHA FUNCTIONAL CLASS III OR IV) IN THOSE PATIENTS WHO REMAIN SYMPTOMATIC DESPITE STABLE, OPTIMAL, MEDICAL THERAPY, AND HAVE A LEFT VENTRICULAR EJECTION FRACTION <= 35% AND A QRS DURATION = 130 MS. 2) THE ATTAIN LV MODEL 2187 LEAD HAS APPLICATION AS PART OF A MEDTRONIC BIVENTRICULAR PACING SYSTEM. 3) THE ATTAIN CS MODEL 2188 LEAD HAS APPLICATION WHERE PERMANENT ATRIAL, OR FUAL-CHAMBER PACING SYSTEMS ARE INDICATED, OR AS PART OF A MEDTRONIC BIVENTRICULAR PACING SYSTEM.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Aug 28, 2001

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010015
Regulatory pathway
Premarket approval application
Product code
LWP
Decision code
APPR
Decision date
Aug 28, 2001
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable pulse generator, pacemaker (non-CRT).

Product code
LWP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P010015 received

    Application receipt date recorded by FDA.

  2. P010015 · FDA decision

    APPR

  3. P010015/S590 · Related supplement

    Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P

  4. P010015/S591 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  5. P010015/S592 · Related supplement

    Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010015

Explore the linked device profile

Other records with product code LWP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records